Los Angeles Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Los Angeles Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.62M	Sell	137,929 -16,493	-11%	-$384K	0.01%	469
2026 Q1	$3.64M	Buy	154,422 +89,919	+139%	+$2.29M	0.01%	387
2025 Q4	$1.61M	Buy	64,503 +1,478	+2%	+$37.8K	0.01%	497
2025 Q3	$1.19M	Buy	63,025 +32,162	+104%	+$507K	﹤0.01%	659
2025 Q2	$433K	Hold	30,863	–	–	﹤0.01%	910
2025 Q1	$483K	Buy	30,863 +70	+0.2%	+$986	﹤0.01%	753
2024 Q4	$429K	Sell	30,793 -94,310	-75%	-$1.03M	﹤0.01%	847
2024 Q3	$1.16M	Sell	125,103 -10,845	-8%	-$107K	﹤0.01%	604
2024 Q2	$1.26M	Sell	135,948 -12,485	-8%	-$113K	﹤0.01%	572
2024 Q1	$1.47M	Sell	148,433 -46,028	-24%	-$344K	0.01%	573
2023 Q4	$628K	Buy	+194,461	New	+$529K	﹤0.01%	814
2022 Q2	–	Sell	-26,257	Closed	-$506K	–	1323
2022 Q1	$506K	Sell	26,257 -1,720	-6%	-$29.1K	﹤0.01%	1019
2021 Q4	$580K	Buy	27,977 +7	+0%	+$139	﹤0.01%	936
2021 Q3	$668K	Buy	27,970 +1,280	+5%	+$29.2K	﹤0.01%	925
2021 Q2	$728K	Buy	+26,690	New	+$752K	﹤0.01%	1000

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Los Angeles Capital Management's ARQT Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Arcutis Biotherapeutics (ARQT) stake by 11% in Q2 2026, selling an estimated $384K and leaving 137,929 shares worth $3.62M. The position accounts for 0.01% of the portfolio, ranked #469.

Los Angeles Capital Management first reported a position in ARQT in Q2 2021 and has held it in 15 quarters since. The position peaked at $3.64M in Q1 2026. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Los Angeles Capital Management held 137,929 shares of Arcutis Biotherapeutics worth $3.62M as of Q2 2026.
Los Angeles Capital Management sold 16,493 Arcutis Biotherapeutics shares in Q2 2026, an estimated $384K.
Arcutis Biotherapeutics made up 0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #469 holding.
Los Angeles Capital Management first reported a position in Arcutis Biotherapeutics in Q2 2021 and has held it in 15 quarters since.
Los Angeles Capital Management's Arcutis Biotherapeutics position peaked at $3.64M in Q1 2026.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.